Straits Times Index
3,292.69 +10.64 (+0.32%) Nikkei
38,274.05 -131.61 (-0.34%) Hang Seng
17,763.03 +16.12 (+0.09%) FTSE 100
8,154.38 +10.25 (+0.13%) Bitcoin USD
57,281.80 -4,479.82 (-7.25%) CMC Crypto 200
1,235.29 -103.78 (-7.74%)
Intellia Therapeutics, Inc. (NTLA)
After hours:
| Previous close | 21.98 |
| Open | 21.64 |
| Bid | 21.31 x 200 |
| Ask | 21.43 x 600 |
| Day's range | 21.30 - 21.97 |
| 52-week range | 19.37 - 47.48 |
| Volume | |
| Avg. volume | 1,486,813 |
| Market cap | 2.064B |
| Beta (5Y monthly) | 1.80 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.42 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 70.96 |
GlobeNewswireIntellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
Extended follow-up will include safety, kallikrein reduction and attack rate data, including number of patients who continue to be completely attack free through the latest follow-upIntellia to host investor webcast on Monday, June 3, at 8 a.m. ET CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the acceptance of an oral pre
ZacksIntellia (NTLA) to Report Q1 Earnings: What's in the Cards?
On Intellia's (NTLA) first-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
ZacksEarnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
